کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5969507 1576175 2014 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Cardioprotection for percutaneous coronary intervention - Reperfusion quality as well as quantity
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
Cardioprotection for percutaneous coronary intervention - Reperfusion quality as well as quantity
چکیده انگلیسی


- Translation of cardioprotective agents into useful treatment is challenging.
- Right treatment, in the right patient at the right time will improve effectiveness.
- Trial design must reflect the rules of cardioprotection to demonstrate benefit.

Ischaemia−reperfusion (IR) injury is an important cause of myocardial damage during percutaneous coronary intervention (PCI). There are few therapies in widespread clinical use which impact on IR injury and it remains an important and underutilized target for treatment in acute myocardial infarction. This review will examine the translational scientific evidence for ischaemic conditioning and pharmacological agents including conditioning mimetics such as cyclosporine, anti-inflammatory agents, and those which modify myocardial glucose metabolism. We will address the reasons why many trials have failed to demonstrate clinical benefit and emphasize the need to deliver the right therapy to the right patient, at the right time to achieve successful translation of cardioprotection from bench-to-bedside. We critique trial design and offer advice for future translational trials in the field to ensure that effective treatments can be demonstrated clinically to improve patient outcomes during PCI.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: International Journal of Cardiology - Volume 177, Issue 3, 20 December 2014, Pages 786-793
نویسندگان
, , ,